-
Views
-
Cite
Cite
C. Lesort, A.P. Villani, J. Giai, P.A. Becherel, J. Delaunay, K. Fattouh, E. Ducroux, D. Jullien, P. Guillem, High prevalence of cannabis use among patients with hidradenitis suppurativa: results from the VERADDICT survey, British Journal of Dermatology, Volume 181, Issue 4, 1 October 2019, Pages 839–841, https://doi.org/10.1111/bjd.17930
- Share Icon Share
Extract
For a full list of author institutions, see Appendix S1.
Funding sources: none.
Conflicts of interest: A.P.V. is a consultant for Bailleul (2017), GSK (2017), Janssen (2018) and Novartis (2018); D.J. is a consultant for AbbVie, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sandoz; P.G. is a consultant for AbbVie and Novartis and has provided lectures for AbbVie, Convatec, Cicaplus and Brothier; J.D. is a consultant for Novartis, Janssen, AbbVie, Leo Pharma and Sanofi.
C.L. and A.P.V. contributed equally as first authors; D.J. and P.G. contributed equally as last authors.
Dear Editor, Garg et al.1 recently highlighted that cannabis use was more common in patients with hidradenitis suppurativa (HS) (1·2%) compared with the general population (0·4%). However, the reasons why patients with HS are more prone to cannabis abuse are unknown: one can hypothesize that cannabis could be a trigger of the disease or a consequence of the chronic pain associated with HS. Our aims were to determine the prevalence and reasons for cannabis use in patients with HS.